# Novartis invests €104M to expand Ivrea radiopharmaceutical plant in Italy

Novartis inaugurated a new 3,000-square-meter facility at its Ivrea site in Colleretto Giacosa, Italy, with an investment of €84 million over three years to boost production of radioligand therapies for prostate cancer. An additional €20 million was allocated for a new building for diagnostic products and R&D.

- Type: Expansion
- Announced: 2023-10-20
- Where: Colleretto Giacosa, Ivrea, Piedmont, Italy, Italy
- Value: $110.0M (104.0M EUR)
- Starts operating: 20 Oct 2023
- Status: completed
- Capacity: 3,000 square meters
- Products: radioligand therapies, diagnostic products
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novartis](https://endata.com/companies/32041.md)

## Sources

- [sanitainformazione.it](https://www.sanitainformazione.it/novartis-investe-in-piemonte-oltre-100-mln-di-euro-per-ampliare-il-polo-di-ivrea/), 2023-10-20: "Novartis investe in Piemonte e rafforza la sua presenza sul territorio con l’ampliamento del polo di Ivrea, fiore all’occhiello per l’Italia nell’innovazione oncologica."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.